Cardiol Therapeutics (CRDL) Cash from Financing Activities (2020 - 2026)

Cardiol Therapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at $9.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 102887.35% year-over-year to $9.9 million; the trailing twelve-month figure through Mar 2026 stood at $21.1 million (up 56.96% YoY), and the FY2025 full-year result was $11.1 million, down 17.38% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $9.9 million, down from $11.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $13.4 million in Q4 2024, with the low at -$10614.8 in Q3 2022.
• Historically, Cash from Financing Activities has averaged $2.0 million across 5 years, with a median of -$10059.5 in 2025.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 131673.49% — and 2025, when it tumbled 197.35%.
• Cardiol Therapeutics' Cash from Financing Activities stood at -$10198.9 in 2022, then climbed by 0.29% to -$10168.9 in 2023, then surged by 131673.49% to $13.4 million in 2024, then retreated by 16.67% to $11.1 million in 2025, then declined by 11.05% to $9.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $9.9 million (Q1 2026), $11.1 million (Q4 2025), and -$10059.5 (Q3 2025), per Business Quant data.